Coherus Oncology, Inc. (CHRS)

Market Cap	266.80M +101.4%
Revenue (ttm)	42.17M +59.8%
Net Income	168.02M +489.4%
EPS	1.43 +476.4%
Shares Out	149.89M
PE Ratio	1.24
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,398,579
Open	1.970
Previous Close	1.950
Day's Range	1.780 - 1.995
52-Week Range	0.710 - 2.616
Beta	1.09
Analysts	Strong Buy
Price Target	5.51 (+209.55%)
Earnings Date	Mar 9, 2026

About CHRS

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2014
• Employees: 147
• Stock Exchange: NASDAQ
• Ticker Symbol: CHRS
• Website: https://www.coherus.com

Financial Performance

In 2025, Coherus Oncology's revenue was $42.17 million, an increase of 59.81% compared to the previous year's $26.39 million. Earnings were $168.02 million, an increase of 489.41%.

Analyst Summary

According to 4 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price target is $5.51, which is an increase of 209.55% from the latest price.

Price Target

$5.51

(209.55% upside)

Analyst Consensus: Strong Buy